Compare IDEXX Laboratories, Inc. (IDXX) vs Samsara Inc (IOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Samsara Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Samsara Inc trades at $41.55 (market cap $24.14B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Samsara Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Samsara Inc for 19 Days on average.
| IDXX | IOT | |
|---|---|---|
Market Cap | $40.43B | $24.14B |
Volume | 692,164 | 5,372,580 |
Sector | Health | Technology |
52-Week High | $766.68 | $45.22 |
52-Week Low | $504.70 | $24.25 |
Typical Hold Time | 46 Days | 19 Days |
Enterprise Value | $41.32B | $23.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Samsara (IOT) trades at $41.55, up 2.57% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $0.20 exceeding the $0.16 forecast. Revenue growth is robust, projected to rise from $1.25B in 2025 to $1.8B in 2026, while the company transitions to profitability with a net margin of 4.9% in 2026. Recent partnerships and product launches, like the Laval Rocket sponsorship and Samsara MCP, highlight ongoing business expansion.
The outlook is positive, driven by 30% annual recurring revenue growth and large-customer adoption, though high valuation multiples (P/E 274.8, P/S 13.01) pose a risk if growth slows. Analyst consensus is strongly bullish with a $51.15 price target, but investors should monitor cash flow pressures and competitive threats in the connected operations software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →
